Immunitybio Stock Cash Flow From Operations
| IBRX Stock | USD 3.47 0.31 9.81% |
Immunitybio fundamentals help investors to digest information that contributes to Immunitybio's financial success or failures. It also enables traders to predict the movement of Immunitybio Stock. The fundamental analysis module provides a way to measure Immunitybio's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Immunitybio stock.
Immunitybio |
Immunitybio Company Cash Flow From Operations Analysis
Immunitybio's Operating Cash Flow reveals the quality of a company's reported earnings and is calculated by deducting company's income taxes from earnings before interest, taxes, and depreciation (EBITDA). In other words, Operating Cash Flow refers to the amount of cash a firm generates from the sales or products or from rendering services. Operating Cash Flow typically excludes costs associated with long-term investments or investment in marketable securities and is usually used by investors or analysts to check on the quality of a company's earnings.
Current Immunitybio Cash Flow From Operations | (366.76 M) |
Most of Immunitybio's fundamental indicators, such as Cash Flow From Operations, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Immunitybio is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Operating Cash Flow shows the difference between reported income and actual cash flows of the company. If a firm does not have enough cash or cash equivalents to cover its current liabilities, then both investors and management should be concerned about the company having enough liquid resources to meet current and long term debt obligations.
| Competition |
In accordance with the recently published financial statements, Immunitybio has (366.76 Million) in Cash Flow From Operations. This is 169.56% lower than that of the Biotechnology sector and significantly lower than that of the Health Care industry. The cash flow from operations for all United States stocks is 137.76% higher than that of the company.
Immunitybio Cash Flow From Operations Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Immunitybio's direct or indirect competition against its Cash Flow From Operations to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Immunitybio could also be used in its relative valuation, which is a method of valuing Immunitybio by comparing valuation metrics of similar companies.Immunitybio is currently under evaluation in cash flow from operations category among its peers.
Immunitybio Fundamentals
| Return On Asset | -0.56 | ||||
| Operating Margin | (13.14) % | ||||
| Current Valuation | 3.15 B | ||||
| Shares Outstanding | 730.16 M | ||||
| Shares Owned By Insiders | 73.50 % | ||||
| Shares Owned By Institutions | 9.61 % | ||||
| Number Of Shares Shorted | 54.54 M | ||||
| Price To Sales | 345.56 X | ||||
| Revenue | 622 K | ||||
| Gross Profit | 7.33 M | ||||
| EBITDA | (436.18 M) | ||||
| Net Income | (583.2 M) | ||||
| Cash And Equivalents | 82.94 M | ||||
| Cash Per Share | 0.21 X | ||||
| Total Debt | 726.72 M | ||||
| Current Ratio | 0.31 X | ||||
| Book Value Per Share | (1.07) X | ||||
| Cash Flow From Operations | (366.76 M) | ||||
| Short Ratio | 9.56 X | ||||
| Earnings Per Share | (0.90) X | ||||
| Price To Earnings To Growth | 3.69 X | ||||
| Target Price | 12.19 | ||||
| Number Of Employees | 672 | ||||
| Beta | -0.43 | ||||
| Market Capitalization | 2.53 B | ||||
| Total Asset | 504.45 M | ||||
| Retained Earnings | (2.96 B) | ||||
| Working Capital | 235.8 M | ||||
| Net Asset | 504.45 M |
About Immunitybio Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Immunitybio's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Immunitybio using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Immunitybio based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Immunitybio Stock Analysis
When running Immunitybio's price analysis, check to measure Immunitybio's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Immunitybio is operating at the current time. Most of Immunitybio's value examination focuses on studying past and present price action to predict the probability of Immunitybio's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Immunitybio's price. Additionally, you may evaluate how the addition of Immunitybio to your portfolios can decrease your overall portfolio volatility.